Turning high potential into high performance.

• - Founding Director of NCL
• - CIO of Ashberg Ltd
• - Director of funds distribution for NTGI
• - Director at HSBC Securities
• - Director at BoS Investments
• - Holds the IMC, IAQ and is an FCA Approved Person (CF1/CF30)
• - Board positions on various tech SMEs

- PA to the Chairman of London Newcastle
- PA and HR Assistant at Devon and Cornwall Housing Association
- PA to the founder of a Charity Mail Order business in West Cornwall

• - CIO for two technology focused, Family Offices
• - Selection and active Board Membership through to exit of several successful SMEs
• - Founder of high growth health and wellness business
• - EasyGroup new ventures business manager
• - Developer of UKs first reverse auction website
• - Holds an MBA from INSEAD

- 2 years working in Venture Capital covering multiple verticals, primarily Medical Technology and Life Sciences
- Previous work at the United Nations and the Chilean Foreign Office
- Consultant with Jaguar Land Rover
- MPhil in Management from the University of Cambridge
- MA, First Class from the University of St. Andrews

- Originally trained as doctor and a surgeon
- Previously - 3i Private Equity, Pangaea Investors
- Senior leadership and advisory roles in the life-sciences sector
- Regular lecturer at Cambridge, Imperial and Stanford
- Holds a degree in medicine, degree in law, master’s degree in Surgical Technology and MBA from London Business School

- Founder of a menopause business and community
- Holds degrees in Neuroscience (BSc Hon) and Finance (MSc)
- Previously in Corporate Finance, focusing on lifesciences and medical businesses
- Competitive athlete (2x European Junior Karate Champion)

Mr. O'Neill is an experienced entrepreneurial business owner and corporate executive.

Mr. O'Neill is President of Kent Life Science Fund II, US and a member of the Investment Committee of the Fund. Previously Mr. O'Neill was co-founder and Managing Partner of KOM Capital LLC, a $1.2Bn alternative asset management firm focused on the Life Sciences and early stage energy sectors. Concurrently Mr. O'Neill served as non-executive Chairman of CCF 2, a China focused pre-IPO private equity fund and also has served as non-executive Chairman of SilkRoad China Asset Management LLC, a Hong Kong, investment fund focused on Asian listed securities.

Previously Mr. O'Neill held senior positions as President & Founder, Stewart & Company, a listed institutional asset management firm; Metzler Bank, N.A. as Co-Head, Americas; Canadian Imperial Bank of Commerce ("CIBC") as Managing Director and Senior Vice President, US; and Pitney Bowes Corporation as Controller.
Mr. O'Neill is a graduate of Quinnipiac University and is a Certified Public Accountant (inactive).

• - 35 years as an applied engineer in both pharma and energy sectors
• - Business Manager Technology Centres at National Renewable Energy Centre (now Offshore Renewable Energy Catapult), Program Manager ERDF Inward Investment and Incubation Project
• - Commercialisation Director at PERA, Manager Yorkshire Forward Innovation Practitioner program
• - Business Manager/ Technology Specialist SKF Condition Monitoring/Asset Management Systems
• - Business Manager/Technology Specialist (Pharma process sterile integrity testing) Pall Pharmaceutical
• - Holds a degree in Aerospace systems

• - 20 years in Senior Management Commercial and Business Development functions in Pharmaceutical and Biotechnology sector
• - Director of New Product Development & Executive Board Director
• - Launched several small molecule & biologics worldwide
• - 10 years early stage commercialisation experience raising £14m funding (capital, equity, grants)
• - Founder of pre-clinical and regulatory organisation to support early stage therapeutic & medical device commercialisation
• - Commercialisation Advisor to several UK universities

• - CFO at Precision Medicine Catapult Ltd
• - Finance Director at Innovate UK (Managing £650M of government innovation funding).
• - Commercial Director at Firstpoint Healthcare
• - Senior Finance Manager at Vodafone
• - Financial Controller Northern Europe at FedEx

• - Chairman of Places for People
• - Chairman of London & Newcastle
• - Member of Octopus Healthcare Advisory Board
• - Chairman of Horizon Infrastructure Partners
• - Managing Director of PB Securities
• - MD Lombard Odier UK Broking business
• - MD Colliers International UK

• - Currently on the board of several technology SMEs including Starglass SA and Expo Technologies
• - Chairman of Coomtech Ltd
• - 30 years experience managing significant change for international industrial businesses
• - Formerly CEO of Delta plc
• - Formerly Managing Director of GKN Driveline worldwide
• - Has a track record for successfully managing investments through the complete cycle, from identification to exit

• - 40 years of technology investment experience
• - Founder and Global CEO of Andersen Corporate Finance ($1bn p.a. revenue UK, US, Europe, Asia)
• - CFO and NED in several disruptive technology companies both publicly quoted (UK/USA) and private
• - Former Global Managing Partner of Big 5 firm
• - Former Fellow of ICAEW and Associate Member of Securities Institute
• - BA Hons, First Class, in Business and Finance

Director of the Sackler Institute of Pulmonary Pharmacology at King’s College London. Internationally recognized in the pharmacology of inflammatory and respiratory diseases, with over 250 scientific papers. He was the co-founder and former Chairman at Verona Pharma plc (AIM listed), a NED of Babraham Biotechnology, Peptinnovate, Prep Biopharma and Epiendo. He was awarded an OBE for “Services to Pharmacology” in the Queen’s Birthday Honors List in 2017.

Professor of Cancer Therapeutics at University of Kent and Visiting Professor at the Institute of Cancer Research. Previously worked at Onyx Pharmaceuticals developing therapeutic products including the CDK4 inhibitor project, which went onto deliver Ibrance® (Palbociclib). Reader in Cancer Therapeutics and Head of Biology for the CRUK Cancer Therapeutics Unit. Michelle currently has three cancer drugs in the clinic.

Pharma R&D at both Roche and Pfizer. Whilst at Pfizer he helped successfully develop a novel therapy for treatment of HIV infection. Mike also headed up Pfizer’s Opportunities for Partnership in Medicine (OPM) Research Unit and was a member of the Research Leadership Team at Pfizer’s R&D UK Laboratories. Mike is CEO of Centuari Therapeutics and previously Agalimune Ltd.

Martin is the MD of Medway Community Healthcare and Chairman of Albion Outlook, covering 3 regions and over 30,000 patients. Martin joined NHS Medway from Ashford Primary Care Trust. He has a long-standing career in health, which has involved roles in commissioning, primary care and operations.